US Bancorp DE Raises Stock Holdings in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE)

US Bancorp DE boosted its holdings in shares of iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) by 137.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 384 shares of the company’s stock after acquiring an additional 222 shares during the quarter. US Bancorp DE’s holdings in iShares U.S. Pharmaceuticals ETF were worth $27,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of IHE. McElhenny Sheffield Capital Management LLC purchased a new position in shares of iShares U.S. Pharmaceuticals ETF during the second quarter worth approximately $18,942,000. Aptus Capital Advisors LLC purchased a new position in iShares U.S. Pharmaceuticals ETF during the 2nd quarter worth $12,165,000. Rockport Wealth LLC bought a new stake in iShares U.S. Pharmaceuticals ETF during the 2nd quarter valued at $12,091,000. Kraft Davis & Associates LLC lifted its holdings in shares of iShares U.S. Pharmaceuticals ETF by 116.8% in the 1st quarter. Kraft Davis & Associates LLC now owns 24,294 shares of the company’s stock worth $1,590,000 after buying an additional 13,088 shares during the period. Finally, Marshall Wace LLP bought a new position in shares of iShares U.S. Pharmaceuticals ETF during the 2nd quarter worth $422,000.

iShares U.S. Pharmaceuticals ETF Price Performance

IHE stock opened at $66.60 on Tuesday. iShares U.S. Pharmaceuticals ETF has a 1-year low of $57.62 and a 1-year high of $72.94. The business has a 50-day moving average price of $70.33 and a 200 day moving average price of $68.70. The company has a market capitalization of $672.66 million, a P/E ratio of 6.49 and a beta of 0.58.

iShares U.S. Pharmaceuticals ETF Company Profile

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.